Chinese medicine stock R & D expense ranking list is released! Tasly, Red Sun, Katazai 9 more than 100 million, Jianmin, Huluwa 12 growth rate of more than 50%

A few days ago, the performance disclosure of listed companies in the first half of 2022 came to an end, 449 pharmaceutical companies have handed over report cards, and the research and development expenses of Traditional Chinese medicine companies are also the

5 R & D expenses exceeded 200 million, and Hongri Pharmaceutical and Katazai zhenjin entered the echelon of 100 million yuan

A-share Chinese medicine enterprise with R&D expenditure of more than 100 million yuan in the first half of 2022 (: 10,000 yuan)

Tasly expands the company's research pipeline through the "four-in-one" drug innovation and development model of independent research and development, product introduction, cooperative research and development, and investment market licensing priority, and steadily promotes the research and development progress

Focusing on research and innovation in the fields of severe disease, oncology and immunity, cardiovascular and cerebrovascular diseases, respiratory system and other fields, Hongri Pharmaceutical has developed into a high-tech pharmaceutical and health industry cluster integrating investment and financing, research and development, production and sales across many fields such as traditional Chinese medicine formula granules, finished drugs, medical devices

Jianmin, Huluwa.

In recent years, Jianmin Group has continued to increase R&D investment, accelerated the development and approval of new products, and orderly promoted the secondary development of old products, with R&D expenses increasing by more than 80% year-on-year in the first half of the

Huluwa has long focused on the field of children's medicine, focusing on drug research and development, production, sales, product categories covering characteristic Traditional Chinese medicine, chemical drugs, etc.

14 R&D expenses accounted for more than 5%

In the first half of 2022, R&D expenses accounted for more than 5% of revenue for A-share Chinese medicine enterprises (: 10,000 yuan)

Longjin Pharmaceutical has been engaged in the research and development, production and sales of modern proprietary Chinese medicines and high-end chemical generic drugs, and in recent years has invested in the establishment of subsidiaries to engage in innovative drug research and development, high-end chemical generic drug research and development, industrial hemp cultivation and other businesses

Guilin Sanjin's main business is the research and development, manufacturing and sales of proprietary Chinese medicines, covering chemical preparations, biological agents, daily health care products and other subdivisions, the company has formed a leading or leading position

epilogue

In recent years, the state has continued to encourage the innovation of traditional Chinese medicine from many aspects such as research and development, taxation, and special funds, and stimulated market vitality